Australia markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.70-1.98 (-4.53%)
At close: 04:00PM EST
41.70 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Previous close43.68
Open43.80
Bid37.00 x 900
Ask45.00 x 900
Day's range41.18 - 43.93
52-week range27.50 - 73.00
Volume1,022,846
Avg. volume1,859,792
Market cap4.06B
Beta (5Y monthly)1.62
PE ratio (TTM)N/A
EPS (TTM)-6.47
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est68.75
  • GlobeNewswire

    Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

    WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format. The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of t

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

    WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,312,500 shares at the public offering price of $40.00 per share. The exercise of the option to purchase additional shares brought the total number

  • GlobeNewswire

    Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 8,750,000 shares of its common stock at a public offering price of $40.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. All of the shares in the offering are being sold by Apellis.